Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-12-04

AUTHORS

Panpan Liu, Zhijun Huang, Mingzhu Yin, Chun Liu, Xiang Chen, Pinhua Pan, Yehong Kuang

ABSTRACT

ObjectivesA severe epidemic of COVID-19 has broken out in China and has become a major global public health event. We focus on the Acute Respiratory Distress Syndrome (ARDS)-like changes and overactivation of Th17 cells (these produce cytokines) in patients with COVID-19. We aim to explore the safety and efficacy of ixekizumab (an injectable drug for the treatment of autoimmune diseases) to prevent organ injury caused by the immune response to COVID-19. Ixekizumab is a human monoclonal antibody that binds to interleukin-17A and inhibits the release of pro-inflammatory cytokines and chemokines.Trial designThe experiment is divided into two stages. In the first stage, the open trial, 3 patients with COVID-19 are treated with ixekizumab, and the safety and efficacy are observed for 7 days. In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. This is a two-center, open-label, randomized controlled pilot trial with 2-arm parallel group design (1:1 ratio).ParticipantsPatients with COVID-19 aged 18-75 with increased Interleukin (IL)-6 levels will be enrolled, but patients with severe infections requiring intensive care will be excluded. The trial will be undertaken in two centers. The first stage is carried out in Xiangya Hospital of Central South University, and the second stage is carried out simultaneously in the Third Xiangya Hospital of Central South University.Intervention and comparatorIn the first stage, three subjects are given ixekizumab (“Taltz”) (80 mg/ml, 160 mg as a single hypodermic injection) and antiviral therapy (α-interferon (administer 5 million U by aerosol inhalation twice daily), lopinavir/ritonavir (administer 100mg by mouth twice daily, for the course of therapy no more than 10 days), chloroquine (administer 500mg by mouth twice daily, for the course of therapy no more than 10 days), ribavirin (administer 500mg by intravenous injection two to three times a day, for the course of therapy no more than 10 days), or arbidol (administer 200mg by mouth three times a day, for the course of therapy no more than 10 days), but not more than 3 types). The treatment course of the first stage is 7 days.In the second stage, 40 randomized patients will receive the following treatments--Group 1: ixekizumab (80 mg/ml, 160 mg as a single hypodermic injection) with antiviral therapy (the same scheme as in the first stage); Group 2: antiviral therapy alone (the same scheme as in the first stage). The length of the second treatment course is 14 days.Main outcomesThe primary outcome is a change in pulmonary CT severity score (an imaging tool for assessing COVID-19, which scores on the basis of all abnormal areas involved). Pulmonary CT severity score is assessed on the 7th day, 14th day, or at discharge.RandomisationIn the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. The eLite random system of Nanjing Medical University is used for randomization.Blinding (masking)The main efficacy indicator, the CT results, will be evaluated by the third-party blinded and independent research team.Numbers to be randomised (sample size)In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days.Trial StatusTrial registration number is ChiCTR2000030703 (version 1.7 as of March 19, 2020). The recruitment is ongoing, and the date recruitment was initiated in June 2020. The anticipated date of the end of data collection is June 2021.Trial registrationThe name of the trial register is the Chinese Clinical Trial Registry. The trial registration number is ChiCTR2000030703 (http://www.chictr.org.cn/). The date of trial registration is 10 March 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). More... »

PAGES

999

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-020-04925-8

DOI

http://dx.doi.org/10.1186/s13063-020-04925-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1133099688

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33276811


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimalarials", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "COVID-19", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "China", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chloroquine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interleukin-17", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lopinavir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ribavirin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ritonavir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "SARS-CoV-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Safety", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Th17 Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.452223.0", 
          "name": [
            "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China", 
            "Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China", 
            "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Panpan", 
        "id": "sg:person.0773546447.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773546447.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huang", 
        "givenName": "Zhijun", 
        "id": "sg:person.01165066554.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165066554.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.452223.0", 
          "name": [
            "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China", 
            "Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China", 
            "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yin", 
        "givenName": "Mingzhu", 
        "id": "sg:person.01266357307.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266357307.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "Department of Respiratory and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Chun", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gerontology Center of Xiangya Hospital, Central South University, Changsha, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China", 
            "Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China", 
            "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China", 
            "Gerontology Center of Xiangya Hospital, Central South University, Changsha, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Xiang", 
        "id": "sg:person.016317172774.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016317172774.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Respiratory Department, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.452223.0", 
          "name": [
            "The Respiratory Department, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pan", 
        "givenName": "Pinhua", 
        "id": "sg:person.0741230344.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741230344.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.452223.0", 
          "name": [
            "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China", 
            "Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China", 
            "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuang", 
        "givenName": "Yehong", 
        "id": "sg:person.01354636543.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354636543.89"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2020-12-04", 
    "datePublishedReg": "2020-12-04", 
    "description": "ObjectivesA severe epidemic of COVID-19 has broken out in China and has become a major global public health event. We focus on the Acute Respiratory Distress Syndrome (ARDS)-like changes and overactivation of Th17 cells (these produce cytokines) in patients with COVID-19. We aim to explore the safety and efficacy of ixekizumab (an injectable drug for the treatment of autoimmune diseases) to prevent organ injury caused by the immune response to COVID-19. Ixekizumab is a human monoclonal antibody that binds to interleukin-17A and inhibits the release of pro-inflammatory cytokines and chemokines.Trial designThe experiment is divided into two stages. In the first stage, the open trial, 3 patients with COVID-19 are treated with ixekizumab, and the safety and efficacy are observed for 7 days. In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. This is a two-center, open-label, randomized controlled pilot trial with 2-arm parallel group design (1:1 ratio).ParticipantsPatients with COVID-19 aged 18-75 with increased Interleukin (IL)-6 levels will be enrolled, but patients with severe infections requiring intensive care will be excluded. The trial will be undertaken in two centers. The first stage is carried out in Xiangya Hospital of Central South University, and the second stage is carried out simultaneously in the Third Xiangya Hospital of Central South University.Intervention and comparatorIn the first stage, three subjects are given ixekizumab (\u201cTaltz\u201d) (80 mg/ml, 160 mg as a single hypodermic injection) and antiviral therapy (\u03b1-interferon (administer 5 million U by aerosol inhalation twice daily), lopinavir/ritonavir (administer 100mg by mouth twice daily, for the course of therapy no more than 10 days), chloroquine (administer 500mg by mouth twice daily, for the course of therapy no more than 10 days), ribavirin (administer 500mg by intravenous injection two to three times a day, for the course of therapy no more than 10 days), or arbidol (administer 200mg by mouth three times a day, for the course of therapy no more than 10 days), but not more than 3 types). The treatment course of the first stage is 7 days.In the second stage, 40 randomized patients will receive the following treatments--Group 1: ixekizumab (80 mg/ml, 160 mg as a single hypodermic injection) with antiviral therapy (the same scheme as in the first stage); Group 2: antiviral therapy alone (the same scheme as in the first stage). The length of the second treatment course is 14 days.Main outcomesThe primary outcome is a change in pulmonary CT severity score (an imaging tool for assessing COVID-19, which scores on the basis of all abnormal areas involved). Pulmonary CT severity score is assessed on the 7th day, 14th day, or at discharge.RandomisationIn the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. The eLite random system of Nanjing Medical University is used for randomization.Blinding (masking)The main efficacy indicator, the CT results, will be evaluated by the third-party blinded and independent research team.Numbers to be randomised (sample size)In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days.Trial StatusTrial registration number is ChiCTR2000030703 (version 1.7 as of March 19, 2020). The recruitment is ongoing, and the date recruitment was initiated in June 2020. The anticipated date of the end of data collection is June 2021.Trial registrationThe name of the trial register is the Chinese Clinical Trial Registry. The trial registration number is ChiCTR2000030703 (http://www.chictr.org.cn/). The date of trial registration is 10 March 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13063-020-04925-8", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8351885", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8875581", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8339084", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "efficacy of ixekizumab", 
      "CT severity score", 
      "antiviral therapy", 
      "Central South University", 
      "Xiangya Hospital", 
      "treatment course", 
      "severity score", 
      "study protocol", 
      "COVID-19", 
      "registration number", 
      "acute respiratory distress syndrome", 
      "Chinese Clinical Trial Registry", 
      "South University", 
      "Interventional Trials guidelines", 
      "second treatment course", 
      "respiratory distress syndrome", 
      "Clinical Trials Registry", 
      "Third Xiangya Hospital", 
      "TRIAL REGISTRATION NUMBER", 
      "pro-inflammatory cytokines", 
      "Standard Protocol Items", 
      "Nanjing Medical University", 
      "parallel group design", 
      "human monoclonal antibody", 
      "main efficacy indicators", 
      "global public health event", 
      "full protocol", 
      "Th17 cells", 
      "Trials Register", 
      "distress syndrome", 
      "organ injury", 
      "interleukin-17A", 
      "primary outcome", 
      "Trials Registry", 
      "antiviral treatment", 
      "Controlled Trials", 
      "open trial", 
      "intensive care", 
      "TRIAL REGISTRATION", 
      "Trials website", 
      "Trials guidelines", 
      "severe infections", 
      "public health events", 
      "immune response", 
      "pilot trial", 
      "ixekizumab", 
      "Protocol Items", 
      "group 2", 
      "patients", 
      "group 1", 
      "CT results", 
      "efficacy indicators", 
      "Medical University", 
      "monoclonal antibodies", 
      "health events", 
      "therapy", 
      "like changes", 
      "trials", 
      "efficacy", 
      "hospital", 
      "independent research teams", 
      "days", 
      "treatment", 
      "scores", 
      "safety", 
      "two-center", 
      "structured summary", 
      "group", 
      "group design", 
      "severe epidemics", 
      "ParticipantsPatients", 
      "interleukin", 
      "chemokines", 
      "cytokines", 
      "registry", 
      "syndrome", 
      "injury", 
      "infection", 
      "overactivation", 
      "recruitment", 
      "protocol", 
      "antibodies", 
      "care", 
      "course", 
      "intervention", 
      "outcomes", 
      "epidemic", 
      "randomization", 
      "research team", 
      "summary", 
      "Register", 
      "stage", 
      "subjects", 
      "date", 
      "guidelines", 
      "data collection", 
      "cells", 
      "changes", 
      "release", 
      "response", 
      "dissemination", 
      "number", 
      "levels", 
      "recommendations", 
      "discharge", 
      "second stage", 
      "center", 
      "team", 
      "events", 
      "pilot", 
      "University", 
      "first stage", 
      "indicators", 
      "items", 
      "samples", 
      "registration", 
      "key elements", 
      "end", 
      "length", 
      "results", 
      "collection", 
      "accordance", 
      "files", 
      "websites", 
      "additional files", 
      "interest", 
      "materials", 
      "China", 
      "system", 
      "design", 
      "name", 
      "experiments", 
      "formatting", 
      "letter", 
      "elements", 
      "random systems"
    ], 
    "name": "Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial", 
    "pagination": "999", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1133099688"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-020-04925-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33276811"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-020-04925-8", 
      "https://app.dimensions.ai/details/publication/pub.1133099688"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_844.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13063-020-04925-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04925-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04925-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04925-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04925-8'


 

This table displays all metadata directly associated to this object as RDF triples.

342 TRIPLES      20 PREDICATES      182 URIs      174 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-020-04925-8 schema:about N08bed8a1acc94f47948864bfc23109fb
2 N19b82158419e4e46a83c4c2405254c9b
3 N1d847cb7f62843bd87d5eb61d5951a4f
4 N25d1b9479e34405e87b098a3d02053c7
5 N2f630192cc634638af74b1df6c5bb228
6 N327ea61d37ab43cba0fc6e4699979f4e
7 N329d9f6ebda24098b38a3ea751d43544
8 N69ac415ec661469fa016cdc368eb684f
9 N6f1ec62661564a3e9657b116b6830876
10 N7518fc27d85e47d790372fbcd557a963
11 N7c9d8b1c93f540ebb4414305aa654491
12 N7ccf22a4f96740d08a50c6af570c2996
13 N7e593f68abc443db9045ef6a4d5a27f9
14 N80ebbb9d7ef44a40a08bc8187af24334
15 N9556bc5a5dd74882a87e3a072855bf60
16 N98a7307522a647f7a50fdc3cf86ac3f4
17 Nbff8fa3331434206a18d9f889882aeae
18 Nc89e27eb7f50444da11ca8e49f2a80bc
19 Ncf89cb44daa8410bbf7f8946e78fb615
20 Nd61158fa42de4f81b6d55be3c956509a
21 Nf239f6cdace646d8b5080c6e5a9e1b36
22 anzsrc-for:11
23 anzsrc-for:1103
24 schema:author N9e7f9068e07d4cff8fd0bdc6cb2bd8d3
25 schema:datePublished 2020-12-04
26 schema:datePublishedReg 2020-12-04
27 schema:description ObjectivesA severe epidemic of COVID-19 has broken out in China and has become a major global public health event. We focus on the Acute Respiratory Distress Syndrome (ARDS)-like changes and overactivation of Th17 cells (these produce cytokines) in patients with COVID-19. We aim to explore the safety and efficacy of ixekizumab (an injectable drug for the treatment of autoimmune diseases) to prevent organ injury caused by the immune response to COVID-19. Ixekizumab is a human monoclonal antibody that binds to interleukin-17A and inhibits the release of pro-inflammatory cytokines and chemokines.Trial designThe experiment is divided into two stages. In the first stage, the open trial, 3 patients with COVID-19 are treated with ixekizumab, and the safety and efficacy are observed for 7 days. In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. This is a two-center, open-label, randomized controlled pilot trial with 2-arm parallel group design (1:1 ratio).ParticipantsPatients with COVID-19 aged 18-75 with increased Interleukin (IL)-6 levels will be enrolled, but patients with severe infections requiring intensive care will be excluded. The trial will be undertaken in two centers. The first stage is carried out in Xiangya Hospital of Central South University, and the second stage is carried out simultaneously in the Third Xiangya Hospital of Central South University.Intervention and comparatorIn the first stage, three subjects are given ixekizumab (“Taltz”) (80 mg/ml, 160 mg as a single hypodermic injection) and antiviral therapy (α-interferon (administer 5 million U by aerosol inhalation twice daily), lopinavir/ritonavir (administer 100mg by mouth twice daily, for the course of therapy no more than 10 days), chloroquine (administer 500mg by mouth twice daily, for the course of therapy no more than 10 days), ribavirin (administer 500mg by intravenous injection two to three times a day, for the course of therapy no more than 10 days), or arbidol (administer 200mg by mouth three times a day, for the course of therapy no more than 10 days), but not more than 3 types). The treatment course of the first stage is 7 days.In the second stage, 40 randomized patients will receive the following treatments--Group 1: ixekizumab (80 mg/ml, 160 mg as a single hypodermic injection) with antiviral therapy (the same scheme as in the first stage); Group 2: antiviral therapy alone (the same scheme as in the first stage). The length of the second treatment course is 14 days.Main outcomesThe primary outcome is a change in pulmonary CT severity score (an imaging tool for assessing COVID-19, which scores on the basis of all abnormal areas involved). Pulmonary CT severity score is assessed on the 7th day, 14th day, or at discharge.RandomisationIn the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. The eLite random system of Nanjing Medical University is used for randomization.Blinding (masking)The main efficacy indicator, the CT results, will be evaluated by the third-party blinded and independent research team.Numbers to be randomised (sample size)In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days.Trial StatusTrial registration number is ChiCTR2000030703 (version 1.7 as of March 19, 2020). The recruitment is ongoing, and the date recruitment was initiated in June 2020. The anticipated date of the end of data collection is June 2021.Trial registrationThe name of the trial register is the Chinese Clinical Trial Registry. The trial registration number is ChiCTR2000030703 (http://www.chictr.org.cn/). The date of trial registration is 10 March 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
28 schema:genre article
29 schema:isAccessibleForFree true
30 schema:isPartOf N1d2b635a1f0f412cbee314b52f3113cc
31 Nf4c8a9ac9fa2433b883821a790360f1e
32 sg:journal.1297400
33 schema:keywords COVID-19
34 CT results
35 CT severity score
36 Central South University
37 China
38 Chinese Clinical Trial Registry
39 Clinical Trials Registry
40 Controlled Trials
41 Interventional Trials guidelines
42 Medical University
43 Nanjing Medical University
44 ParticipantsPatients
45 Protocol Items
46 Register
47 South University
48 Standard Protocol Items
49 TRIAL REGISTRATION
50 TRIAL REGISTRATION NUMBER
51 Th17 cells
52 Third Xiangya Hospital
53 Trials Register
54 Trials Registry
55 Trials guidelines
56 Trials website
57 University
58 Xiangya Hospital
59 accordance
60 acute respiratory distress syndrome
61 additional files
62 antibodies
63 antiviral therapy
64 antiviral treatment
65 care
66 cells
67 center
68 changes
69 chemokines
70 collection
71 course
72 cytokines
73 data collection
74 date
75 days
76 design
77 discharge
78 dissemination
79 distress syndrome
80 efficacy
81 efficacy indicators
82 efficacy of ixekizumab
83 elements
84 end
85 epidemic
86 events
87 experiments
88 files
89 first stage
90 formatting
91 full protocol
92 global public health event
93 group
94 group 1
95 group 2
96 group design
97 guidelines
98 health events
99 hospital
100 human monoclonal antibody
101 immune response
102 independent research teams
103 indicators
104 infection
105 injury
106 intensive care
107 interest
108 interleukin
109 interleukin-17A
110 intervention
111 items
112 ixekizumab
113 key elements
114 length
115 letter
116 levels
117 like changes
118 main efficacy indicators
119 materials
120 monoclonal antibodies
121 name
122 number
123 open trial
124 organ injury
125 outcomes
126 overactivation
127 parallel group design
128 patients
129 pilot
130 pilot trial
131 primary outcome
132 pro-inflammatory cytokines
133 protocol
134 public health events
135 random systems
136 randomization
137 recommendations
138 recruitment
139 registration
140 registration number
141 registry
142 release
143 research team
144 respiratory distress syndrome
145 response
146 results
147 safety
148 samples
149 scores
150 second stage
151 second treatment course
152 severe epidemics
153 severe infections
154 severity score
155 stage
156 structured summary
157 study protocol
158 subjects
159 summary
160 syndrome
161 system
162 team
163 therapy
164 treatment
165 treatment course
166 trials
167 two-center
168 websites
169 schema:name Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial
170 schema:pagination 999
171 schema:productId N112b359e72144f88b96d7a0a1f3d1fcd
172 N2dacc62f964143cbb573b31f717a807b
173 N6d498b86b1c64b33b97923d500c4ca93
174 schema:sameAs https://app.dimensions.ai/details/publication/pub.1133099688
175 https://doi.org/10.1186/s13063-020-04925-8
176 schema:sdDatePublished 2022-11-24T21:06
177 schema:sdLicense https://scigraph.springernature.com/explorer/license/
178 schema:sdPublisher Na45d64aa734d4c77972b31d6150f4d16
179 schema:url https://doi.org/10.1186/s13063-020-04925-8
180 sgo:license sg:explorer/license/
181 sgo:sdDataset articles
182 rdf:type schema:ScholarlyArticle
183 N0699155a47be412998a12cf43419290b rdf:first sg:person.016317172774.87
184 rdf:rest N699c4b261de8419e8e585ae1fea1bf45
185 N08bed8a1acc94f47948864bfc23109fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name SARS-CoV-2
187 rdf:type schema:DefinedTerm
188 N112b359e72144f88b96d7a0a1f3d1fcd schema:name dimensions_id
189 schema:value pub.1133099688
190 rdf:type schema:PropertyValue
191 N19b82158419e4e46a83c4c2405254c9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Ribavirin
193 rdf:type schema:DefinedTerm
194 N1d2b635a1f0f412cbee314b52f3113cc schema:issueNumber 1
195 rdf:type schema:PublicationIssue
196 N1d847cb7f62843bd87d5eb61d5951a4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name China
198 rdf:type schema:DefinedTerm
199 N20da99659fd240ab984183fccd1d029d rdf:first Ne1b864d1e16d4be1946c6636cd9525d6
200 rdf:rest N0699155a47be412998a12cf43419290b
201 N25d1b9479e34405e87b098a3d02053c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Antibodies, Monoclonal, Humanized
203 rdf:type schema:DefinedTerm
204 N2dacc62f964143cbb573b31f717a807b schema:name pubmed_id
205 schema:value 33276811
206 rdf:type schema:PropertyValue
207 N2f630192cc634638af74b1df6c5bb228 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Lopinavir
209 rdf:type schema:DefinedTerm
210 N327ea61d37ab43cba0fc6e4699979f4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Indoles
212 rdf:type schema:DefinedTerm
213 N329d9f6ebda24098b38a3ea751d43544 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Drug Therapy, Combination
215 rdf:type schema:DefinedTerm
216 N699c4b261de8419e8e585ae1fea1bf45 rdf:first sg:person.0741230344.37
217 rdf:rest Nb7a41241c150439494c6da8d587660ca
218 N69ac415ec661469fa016cdc368eb684f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Antimalarials
220 rdf:type schema:DefinedTerm
221 N6d498b86b1c64b33b97923d500c4ca93 schema:name doi
222 schema:value 10.1186/s13063-020-04925-8
223 rdf:type schema:PropertyValue
224 N6f1ec62661564a3e9657b116b6830876 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
225 schema:name Interleukin-17
226 rdf:type schema:DefinedTerm
227 N7518fc27d85e47d790372fbcd557a963 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Case-Control Studies
229 rdf:type schema:DefinedTerm
230 N7c9d8b1c93f540ebb4414305aa654491 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
231 schema:name Safety
232 rdf:type schema:DefinedTerm
233 N7ccf22a4f96740d08a50c6af570c2996 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
234 schema:name COVID-19
235 rdf:type schema:DefinedTerm
236 N7e593f68abc443db9045ef6a4d5a27f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
237 schema:name Aged
238 rdf:type schema:DefinedTerm
239 N80ebbb9d7ef44a40a08bc8187af24334 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
240 schema:name Treatment Outcome
241 rdf:type schema:DefinedTerm
242 N9556bc5a5dd74882a87e3a072855bf60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
243 schema:name Antiviral Agents
244 rdf:type schema:DefinedTerm
245 N98a7307522a647f7a50fdc3cf86ac3f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
246 schema:name Chloroquine
247 rdf:type schema:DefinedTerm
248 N9e7f9068e07d4cff8fd0bdc6cb2bd8d3 rdf:first sg:person.0773546447.61
249 rdf:rest Ne3aca30074064909a8b67263465948cd
250 Na45d64aa734d4c77972b31d6150f4d16 schema:name Springer Nature - SN SciGraph project
251 rdf:type schema:Organization
252 Nb7a41241c150439494c6da8d587660ca rdf:first sg:person.01354636543.89
253 rdf:rest rdf:nil
254 Nbff8fa3331434206a18d9f889882aeae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
255 schema:name Humans
256 rdf:type schema:DefinedTerm
257 Nc89e27eb7f50444da11ca8e49f2a80bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
258 schema:name Ritonavir
259 rdf:type schema:DefinedTerm
260 Ncf89cb44daa8410bbf7f8946e78fb615 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
261 schema:name Adult
262 rdf:type schema:DefinedTerm
263 Nd61158fa42de4f81b6d55be3c956509a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
264 schema:name Th17 Cells
265 rdf:type schema:DefinedTerm
266 Ne1b864d1e16d4be1946c6636cd9525d6 schema:affiliation grid-institutes:grid.216417.7
267 schema:familyName Liu
268 schema:givenName Chun
269 rdf:type schema:Person
270 Ne3aca30074064909a8b67263465948cd rdf:first sg:person.01165066554.34
271 rdf:rest Nf0682f47f27448c79e1a135539233d03
272 Nf0682f47f27448c79e1a135539233d03 rdf:first sg:person.01266357307.80
273 rdf:rest N20da99659fd240ab984183fccd1d029d
274 Nf239f6cdace646d8b5080c6e5a9e1b36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
275 schema:name Middle Aged
276 rdf:type schema:DefinedTerm
277 Nf4c8a9ac9fa2433b883821a790360f1e schema:volumeNumber 21
278 rdf:type schema:PublicationVolume
279 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
280 schema:name Medical and Health Sciences
281 rdf:type schema:DefinedTerm
282 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
283 schema:name Clinical Sciences
284 rdf:type schema:DefinedTerm
285 sg:grant.8339084 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-020-04925-8
286 rdf:type schema:MonetaryGrant
287 sg:grant.8351885 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-020-04925-8
288 rdf:type schema:MonetaryGrant
289 sg:grant.8875581 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-020-04925-8
290 rdf:type schema:MonetaryGrant
291 sg:journal.1297400 schema:issn 1468-6708
292 1745-6215
293 schema:name Trials
294 schema:publisher Springer Nature
295 rdf:type schema:Periodical
296 sg:person.01165066554.34 schema:affiliation grid-institutes:grid.216417.7
297 schema:familyName Huang
298 schema:givenName Zhijun
299 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165066554.34
300 rdf:type schema:Person
301 sg:person.01266357307.80 schema:affiliation grid-institutes:grid.452223.0
302 schema:familyName Yin
303 schema:givenName Mingzhu
304 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266357307.80
305 rdf:type schema:Person
306 sg:person.01354636543.89 schema:affiliation grid-institutes:grid.452223.0
307 schema:familyName Kuang
308 schema:givenName Yehong
309 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354636543.89
310 rdf:type schema:Person
311 sg:person.016317172774.87 schema:affiliation grid-institutes:grid.216417.7
312 schema:familyName Chen
313 schema:givenName Xiang
314 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016317172774.87
315 rdf:type schema:Person
316 sg:person.0741230344.37 schema:affiliation grid-institutes:grid.452223.0
317 schema:familyName Pan
318 schema:givenName Pinhua
319 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741230344.37
320 rdf:type schema:Person
321 sg:person.0773546447.61 schema:affiliation grid-institutes:grid.452223.0
322 schema:familyName Liu
323 schema:givenName Panpan
324 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773546447.61
325 rdf:type schema:Person
326 grid-institutes:grid.216417.7 schema:alternateName Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China
327 Department of Respiratory and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China
328 Gerontology Center of Xiangya Hospital, Central South University, Changsha, China
329 schema:name Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China
330 Department of Respiratory and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China
331 Gerontology Center of Xiangya Hospital, Central South University, Changsha, China
332 Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China
333 Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China
334 The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
335 rdf:type schema:Organization
336 grid-institutes:grid.452223.0 schema:alternateName Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China
337 The Respiratory Department, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China
338 schema:name Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China
339 Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China
340 The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
341 The Respiratory Department, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China
342 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...